

Key Figures on Biosimilars

BIOSIMILARS IN EUROPE



15 YEARS EUROPEAN EXPERIENCE



FIRST BIOSIMILAR
APPROVED IN EUROPE 2006



OVER 2 BILLION
PATIENT DAYS IN EUROPE¹


BIOSIMILARS IN AUSTRALIA



FIRST BIOSIMILAR
IN AUSTRALIA IN 2010



39 BIOSIMILARS
LAUNCHED IN AUSTRALIA²



AVERAGE VOLUME SHARE OF
MOLECULE FOR BIOSIMILARS 42.6%

OUTCOMES



IMPROVED PATIENT ACCESS TO LIFE CHANGING MEDICINES
MORE PATIENTS TREATED FOR THE SAME COST



OVER \$130M IN ANNUAL BIOSIMILAR SALES



OVER \$200M IN ANNUAL PBS SAVINGS DELIVERED
FROM BIOSIMILARS THAT CAN BE INVESTED
INTO NEW INNOVATIVE MEDICINES

1. Source: MIDAS MAT Q2 2020 data; rituximab and trastuzumab DDDs calculated via IQVIA Real World Data, Oncology Dynamics physician surveys on average cycles; pre-2009 analysis includes extrapolated treatment days for biosimilars launched between 2005 – 2008; country cohort includes 30 countries within Europe Economic Area
2. As of Oct 2021.